Free Trial
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

$108.07
-0.06 (-0.06%)
(As of 07/8/2024 ET)
Today's Range
$107.87
$108.79
50-Day Range
$97.13
$108.13
52-Week Range
$92.19
$108.79
Volume
1.43 million shs
Average Volume
1.17 million shs
Market Capitalization
$220.90 billion
P/E Ratio
14.58
Dividend Yield
2.25%
Price Target
$118.13

Novartis MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
9.3% Upside
$118.13 Price Target
Short Interest
Bearish
0.32% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.74mentions of Novartis in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.50%
From $7.28 to $8.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

Medical Sector

683rd out of 876 stocks

Pharmaceutical Preparations Industry

321st out of 416 stocks

NVS stock logo

About Novartis Stock (NYSE:NVS)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Stock Price History

NVS Stock News Headlines

Novartis (NYSE:NVS) PT Raised to $122.50
[Urgent] Hedge Funds Expect Major Crypto Moves
In the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all…
[Urgent] Hedge Funds Expect Major Crypto Moves
In the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all…
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/23/2024
Today
7/08/2024
Next Earnings (Confirmed)
7/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
76,057
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$118.13
High Stock Price Target
$122.50
Low Stock Price Target
$114.00
Potential Upside/Downside
+9.3%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$14.85 billion
Pretax Margin
20.00%

Debt

Sales & Book Value

Annual Sales
$45.44 billion
Cash Flow
$11.11 per share
Book Value
$22.87 per share

Miscellaneous

Outstanding Shares
2,044,000,000
Free Float
2,043,796,000
Market Cap
$220.90 billion
Optionable
Optionable
Beta
0.57

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan M.D. (Age 48)
    Chief Executive Officer
    Comp: $8.01M
  • Mr. Harry Kirsch (Age 59)
    Chief Financial Officer
    Comp: $3.99M
  • Mr. Victor Bulto (Age 46)
    President of US
    Comp: $3.28M
  • Dr. Patrick Horber M.D. (Age 54)
    President of International
    Comp: $7.31M
  • Dr. Steffen Lang Ph.D. (Age 57)
    President of Operations
    Comp: $2.34M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting
  • Ms. Sloan Simpson
    Global Head of Investor Relations
  • Dr. Klaus Moosmayer Ph.D. (Age 56)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.55M
  • Ms. Karen L. Hale (Age 56)
    Chief Legal Officer
    Comp: $2.34M
  • Dr. Robert Kowalski Pharm.D. (Age 56)
    Chief People & Organization Officer
    Comp: $2.1M

Should I Buy Novartis Stock? NVS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Novartis AG:

  • Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally, focusing on therapeutic areas such as cardiovascular, renal, metabolic, and immunology.
  • Novartis AG offers prescription medicines for patients and physicians, providing a wide range of healthcare solutions.

Cons

Investors should be bearish about investing in Novartis AG for these reasons:

  • Novus Energy, Inc. (Novus) is a junior oil and gas company, not related to Novartis AG, which may cause confusion or misinformation for investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

NVS Stock Analysis - Frequently Asked Questions

How have NVS shares performed this year?

Novartis' stock was trading at $100.97 at the beginning of the year. Since then, NVS stock has increased by 7.0% and is now trading at $108.07.
View the best growth stocks for 2024 here
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings results on Tuesday, April, 23rd. The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.73 by $0.07. The business had revenue of $11.83 billion for the quarter, compared to analysts' expectations of $11.50 billion. Novartis had a net margin of 31.33% and a trailing twelve-month return on equity of 32.15%.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Novartis have any subsidiaries?

The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others.

Who are Novartis' major shareholders?

Novartis' top institutional shareholders include Douglas Lane & Associates LLC (0.01%), Boston Common Asset Management LLC (0.01%), Beach Investment Counsel Inc. PA and First Hawaiian Bank.

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD).

This page (NYSE:NVS) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners